Rheumatoid Arthritis

Treatment shows rapid and significant improvements in signs and symptoms of RA after 24 weeks of treatment.

Clinical signs and symptoms of RA may be preceded by a preclinical phase lasting several years.

Lymphoma and lung cancer present significant risk to RA patients.

Birth control use not found to impact disease progression.

Inflammation and joint damage might not be the only factor causing pain in rheumatoid arthritis.

Findings may identify RA patients who need more aggressive treatment.

Pharmacists helping patients evaluate the effectiveness of their RA therapy is likely a better solution for reducing office visits than patient self-monitoring.

RA drug found to improve physical and emotional well-being among patients.

Research may lead to improve rheumatoid arthritis treatment.

Drug shows promise treating chronic and potentially life-threatening skin disease.

Researchers evaluate the benefits of subcutaneous methotrexate compared with the oral version.

Two different dose prescriptions achieve similar results.

Treatment seeks to teach the immune system to ignore a peptide that leads to inflammation.

Researchers seek to improve treatment for autoimmune diseases, including rheumatoid arthritis, gout, Crohn's disease, and lupus.

Rheumatoid arthritis treatment remains consistently well tolerated over long-term evaluation.

Biologics are changing how clinicians make treatment choices.

A number of barriers found in smoking cessation.

Study suggests rheumatoid arthritis chronicity can be influenced.

New treatment approach many help control inflammation.

Researchers explore the use of probiotics to alter communication between brain and immune system.

Compound shows promise in reducing a precursor to RA.

Lithium chloride found to slow degradation.

Researchers study excess fluid from swollen joints of rheumatoid arthritis.

Methotrexate alone superior in efficacy to combination treatment with DMARDs.

Low dose methotrexate more likely to cause infectious adverse events than higher doses of the same drug.

Pfizer executive discusses the present and future of biosimilars.

Research ongoing to target treatment-resistant gout.

Stem cells have been found to target inflammation in osteoarthritis or rheumatoid arthritis.

Lower inflammation scores found in patients with RA receiving statins.

Xeljanz treat adults with moderate to severe active RA who have had an inadequate response or intolerance to methotrexate.